Long-term administration of escitalopram in patients with social anxiety disorder in Japan
Satoshi Asakura,1 Taiji Hayano,2 Atsushi Hagino,2 Tsukasa Koyama3 1Health Care Center and Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, 2Clinical Development Planning and Management, Mochida Pharmaceutical Co., Ltd, Tokyo, 3Clinical Research Center, O...
Guardado en:
Autores principales: | Asakura S, Hayano T, Hagino A, Koyama T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ddd26b8fa0014e00ae56de71289a6a15 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial
por: Jeffrey R. Strawn, et al.
Publicado: (2021) -
Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series
por: Yamaguchi Y, et al.
Publicado: (2018) -
Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
por: Jiang KD, et al.
Publicado: (2017) -
Selective serotonin reuptake inhibitors may lead to improved cataract surgery outcomes in patients with amblyopia
por: Xin KZ, et al.
Publicado: (2019) -
A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
por: Zhong Z, et al.
Publicado: (2017)